Today, lupus treatment in children is based on research conducted on adults. A new study analysed treatment response, damage accrual, and disease activity in 51 children (16 years old or younger) with juvenile-onset lupus nephritis.
The study analysed data collected from juveniles who were treated with mycophenolate mofetil (a drug that prevents organ rejection) or cyclophosphamide (a drug used to treat nephrotic syndrome).
While there were no statistically significant differences identified between the two therapies, researchers concluded that further study should include children with ethnically diverse backgrounds. Ultimately, more research in children with lupus nephritis is needed.
For the full study please click here.